Scientists designed targeted exosomes from mesenchymal stem cells with a chimeric protein against HER2-positive breast cancer, which was used to deliver Dox to HER2-positive cancer cells, resulting in the selective distribution and enhanced antitumor effect of Dox (Gomari et al., 2019). Here, ERBB2 is linked to breast carcinoma.